Clinical Research Directory

Precision Cancer Therapy in Rare Cancers

Sponsor: Oslo University Hospital

Summary

Some rare cancers are hard-to-treat and patients have a poor prognosis. It is known that some of these patients have targetable molecular alterations, and some benefit from targeted drugs. However in many cases these drugs are not approved for the rare cancers. In this study the aim is to do advanced molecular diagnostics to identify possible targets for therapy, and to treat accordingly.

Official title: The MATRIX Clinical Studies of Precision Cancer Therapy for Rare Cancers

Key Details

Conditions

Interventions

Locations (1)